Search Results for: Diabetes

3097 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
AP2M1 and KCNJ11 adaptor-related protein complex 2, mu 1 subunit potassium channel, inwardly rectifying subfamily J, member 11
  • Retrograde neurotrophin signalling
  • Axon guidance
  • Gap junction degradation
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • Gap junction trafficking and regulation
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Formation of annular gap junctions
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Nef mediated downregulation of CD28 cell surface expression
  • Gap junction trafficking
  • Host Interactions of HIV factors
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • PCP/CE pathway
  • Adaptive Immune System
  • Inwardly rectifying K+ channels
  • Integration of energy metabolism
  • ATP sensitive Potassium channels
  • Regulation of insulin secretion
  • Potassium Channels
  • Glimepiride
  • Ibutilide
  • Verapamil
  • Levosimendan
  • Glyburide
  • Diazoxide
  • Thiamylal
AP2M1 and CTLA4 adaptor-related protein complex 2, mu 1 subunit cytotoxic T-lymphocyte-associated protein 4
  • Retrograde neurotrophin signalling
  • Axon guidance
  • Gap junction degradation
  • HIV Infection
  • Nef Mediated CD8 Down-regulation
  • L1CAM interactions
  • Signaling by Wnt
  • Signaling by EGFRvIII in Cancer
  • Recycling pathway of L1
  • EPH-ephrin mediated repulsion of cells
  • Gap junction trafficking and regulation
  • MHC class II antigen presentation
  • EPH-Ephrin signaling
  • Nef Mediated CD4 Down-regulation
  • EGFR downregulation
  • Formation of annular gap junctions
  • Signalling by NGF
  • Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
  • Nef mediated downregulation of CD28 cell surface expression
  • Gap junction trafficking
  • Host Interactions of HIV factors
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • The role of Nef in HIV-1 replication and disease pathogenesis
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • beta-catenin independent WNT signaling
  • Signaling by EGFR
  • WNT5A-dependent internalization of FZD4
  • Signaling by EGFR in Cancer
  • PCP/CE pathway
  • Adaptive Immune System
  • Costimulation by the CD28 family
  • CTLA4 inhibitory signaling
  • Adaptive Immune System
  • Alpha-D-Mannose
CNTN1 and NOTCH2 contactin 1 notch 2
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Axon guidance
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Signaling by NOTCH
  • L1CAM interactions
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Signaling by NOTCH2
  • Neurofascin interactions
  • Signaling by NOTCH1
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Signaling by NOTCH1 in Cancer
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Notch-HLH transcription pathway
  • Signaling by NOTCH2
  • Generic Transcription Pathway
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Transcription and Translation
  • Signaling by NOTCH
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Expression and Processing
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
COPA and MTNR1B coatomer protein complex, subunit alpha melatonin receptor 1B
  • COPI Mediated Transport
  • Golgi to ER Retrograde Transport
  • Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD)
  • Signaling by GPCR
  • GPCR downstream signaling
  • Class A/1 (Rhodopsin-like receptors)
  • G alpha (i) signalling events
  • Metabolic disorders of biological oxidation enzymes
  • GPCR ligand binding
  • Ramelteon
  • Melatonin
  • Agomelatine
CPE and INS carboxypeptidase E insulin
  • Peptide hormone metabolism
  • Insulin processing
  • Synthesis, secretion, and deacylation of Ghrelin
  • Insulin receptor signalling cascade
  • Integration of energy metabolism
  • Regulation of insulin secretion
  • IRS-related events
  • SHC-related events
  • Insulin receptor recycling
  • Peptide hormone metabolism
  • IRS activation
  • Regulation of beta-cell development
  • Signal attenuation
  • Regulation of gene expression in beta cells
  • Insulin processing
  • SHC activation
  • Signaling by Insulin receptor
  • Insulin Regular
  • Insulin, porcine
CREB1 and HNF1B cAMP responsive element binding protein 1 HNF1 homeobox B
  • Signaling by the B Cell Receptor (BCR)
  • Ca-dependent events
  • Signaling by GPCR
  • CaM pathway
  • Phospholipase C-mediated cascade
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • NOTCH2 intracellular domain regulates transcription
  • Signaling by SCF-KIT
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Signaling by NOTCH2
  • PI3K/AKT activation
  • Toll Like Receptor 5 (TLR5) Cascade
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • PKA-mediated phosphorylation of CREB
  • GAB1 signalosome
  • Signaling by NOTCH
  • TRIF-mediated TLR3/TLR4 signaling
  • Opioid Signalling
  • Signaling by ERBB4
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • CREB phosphorylation through the activation of Adenylate Cyclase
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Toll Like Receptor 2 (TLR2) Cascade
  • Signaling by ERBB2
  • PKA-mediated phosphorylation of CREB
  • Signaling by EGFR
  • CREB phosphorylation through the activation of CaMKK
  • AKT phosphorylates targets in the nucleus
  • Calmodulin induced events
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Downstream signal transduction
  • CREB phosphorylation through the activation of CaMKII
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Transmission across Chemical Synapses
  • Adaptive Immune System
  • Organelle biogenesis and maintenance
  • CREB phosphorylation
  • Axon guidance
  • PIP3 activates AKT signaling
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • CREB phosphorylation
  • DAG and IP3 signaling
  • Toll Like Receptor TLR6:TLR2 Cascade
  • CaM pathway
  • Activated TLR4 signalling
  • MyD88 cascade initiated on plasma membrane
  • PI3K events in ERBB2 signaling
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • Downstream signaling of activated FGFR
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • NCAM signaling for neurite out-growth
  • Post NMDA receptor activation events
  • Innate Immune System
  • Signalling by NGF
  • PLC beta mediated events
  • MAP kinase activation in TLR cascade
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • G-protein mediated events
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • Signaling by FGFR
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • PLC-gamma1 signalling
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Nuclear Events (kinase and transcription factor activation)
  • Regulation of beta-cell development
  • Regulation of gene expression in early pancreatic precursor cells
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • Adenosine monophosphate
  • Naloxone
CREBBP and PPARG CREB binding protein peroxisome proliferator-activated receptor gamma
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • PPARA activates gene expression
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Metabolism of lipids and lipoproteins
  • Generic Transcription Pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Nuclear Receptor transcription pathway
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Icosapent
  • Troglitazone
  • Mesalazine
  • Indomethacin
  • Rosiglitazone
  • Nateglinide
  • Sulfasalazine
  • Repaglinide
  • Telmisartan
  • Balsalazide
  • Ibuprofen
  • Glipizide
  • Pioglitazone
  • Mitiglinide
  • Bezafibrate
  • (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid
  • 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID
  • (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid
  • 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID
  • (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid
  • (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid
  • (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid
  • (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid
  • (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid
  • difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron
  • (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID
  • 3-(5-methoxy-1H-indol-3-yl)propanoic acid
  • 3-{5-methoxy-1-[(4-methoxyphenyl)sulfonyl]-1H-indol-3-yl}propanoic acid
  • (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid
  • 2-chloro-5-nitro-N-phenylbenzamide
  • (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid
  • 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid
  • 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID
  • (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid
  • 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE
  • (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid
  • ALEGLITAZAR
CREBBP and HNF4A CREB binding protein hepatocyte nuclear factor 4, alpha
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
CREBBP and HNF1A CREB binding protein HNF1 homeobox A
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Regulation of beta-cell development
  • Regulation of gene expression in beta cells
CREBBP and HNF1B CREB binding protein HNF1 homeobox B
  • Signaling by NOTCH1 HD Domain Mutants in Cancer
  • Metabolism of lipids and lipoproteins
  • Signaling by Wnt
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Generic Transcription Pathway
  • Pre-NOTCH Transcription and Translation
  • RNF mutants show enhanced WNT signaling and proliferation
  • Signaling by NOTCH1 in Cancer
  • Orphan transporters
  • Chromatin organization
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Signaling by NOTCH
  • formation of the beta-catenin:TCF transactivating complex
  • Factors involved in megakaryocyte development and platelet production
  • Chromatin modifying enzymes
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Signaling by NOTCH1 PEST Domain Mutants in Cancer
  • Activation of gene expression by SREBF (SREBP)
  • Transcriptional activation of mitochondrial biogenesis
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • PPARA activates gene expression
  • Cellular response to hypoxia
  • Organelle biogenesis and maintenance
  • Regulation of Hypoxia-inducible Factor (HIF) by oxygen
  • Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
  • Attenuation phase
  • HATs acetylate histones
  • RORA activates circadian gene expression
  • Regulation of cholesterol biosynthesis by SREBP (SREBF)
  • HSF1-dependent transactivation
  • TRAF3-dependent IRF activation pathway
  • Signaling by NOTCH1
  • Transcriptional regulation of white adipocyte differentiation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Pre-NOTCH Expression and Processing
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Innate Immune System
  • FBXW7 Mutants and NOTCH1 in Cancer
  • Fatty acid, triacylglycerol, and ketone body metabolism
  • Cytosolic sensors of pathogen-associated DNA
  • Cellular response to heat stress
  • REV-ERBA represses gene expression
  • Mitochondrial biogenesis
  • Notch-HLH transcription pathway
  • RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
  • NOTCH1 Intracellular Domain Regulates Transcription
  • TCF dependent signaling in response to WNT
  • TRAF6 mediated IRF7 activation
  • YAP1- and WWTR1 (TAZ)-stimulated gene expression
  • Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
  • Signaling by WNT in cancer
  • BMAL1:CLOCK,NPAS2 activates circadian gene expression
  • Regulation of beta-cell development
  • Regulation of gene expression in early pancreatic precursor cells
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
CRK and ERBB3 v-crk avian sarcoma virus CT10 oncogene homolog erb-b2 receptor tyrosine kinase 3
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Platelet Aggregation (Plug Formation)
  • VEGFA-VEGFR2 Pathway
  • Regulation of signaling by CBL
  • Fcgamma receptor (FCGR) dependent phagocytosis
  • Regulation of actin dynamics for phagocytic cup formation
  • Signaling by Insulin receptor
  • Innate Immune System
  • Signaling by PDGF
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • p130Cas linkage to MAPK signaling for integrins
  • Integrin alphaIIb beta3 signaling
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • ARMS-mediated activation
  • Signaling by Interleukins
  • Signal attenuation
  • Signaling by VEGF
  • Downstream signal transduction
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
CRKL and ERBB3 v-crk avian sarcoma virus CT10 oncogene homolog-like erb-b2 receptor tyrosine kinase 3
  • Signaling by PDGF
  • Signalling to ERKs
  • Signalling by NGF
  • Prolonged ERK activation events
  • Signaling by Interleukins
  • Downstream signal transduction
  • Regulation of signaling by CBL
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Interleukin-3, 5 and GM-CSF signaling
  • Frs2-mediated activation
CRKL and NOTCH2 v-crk avian sarcoma virus CT10 oncogene homolog-like notch 2
  • Signaling by PDGF
  • Signalling to ERKs
  • Signalling by NGF
  • Prolonged ERK activation events
  • Signaling by Interleukins
  • Downstream signal transduction
  • Regulation of signaling by CBL
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • Interleukin-3, 5 and GM-CSF signaling
  • Frs2-mediated activation
  • Notch-HLH transcription pathway
  • Signaling by NOTCH2
  • Generic Transcription Pathway
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Transcription and Translation
  • Signaling by NOTCH
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Expression and Processing
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
CRYAB and INS crystallin, alpha B insulin
  • Synthesis, secretion, and deacylation of Ghrelin
  • Insulin receptor signalling cascade
  • Integration of energy metabolism
  • Regulation of insulin secretion
  • IRS-related events
  • SHC-related events
  • Insulin receptor recycling
  • Peptide hormone metabolism
  • IRS activation
  • Regulation of beta-cell development
  • Signal attenuation
  • Regulation of gene expression in beta cells
  • Insulin processing
  • SHC activation
  • Signaling by Insulin receptor
MAPK14 and HNF4A mitogen-activated protein kinase 14 hepatocyte nuclear factor 4, alpha
  • ADP signalling through P2Y purinoceptor 1
  • Cellular Senescence
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor 5 (TLR5) Cascade
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • MyD88 dependent cascade initiated on endosome
  • Toll Like Receptor 9 (TLR9) Cascade
  • ERK/MAPK targets
  • activated TAK1 mediates p38 MAPK activation
  • Regulation of mRNA stability by proteins that bind AU-rich elements
  • CDO in myogenesis
  • TRIF-mediated TLR3/TLR4 signaling
  • Toll Like Receptor 2 (TLR2) Cascade
  • Platelet homeostasis
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Myogenesis
  • Signaling by VEGF
  • Platelet sensitization by LDL
  • Signalling to RAS
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor 3 (TLR3) Cascade
  • Platelet activation, signaling and aggregation
  • Signalling to ERKs
  • Organelle biogenesis and maintenance
  • Toll Like Receptor 7/8 (TLR7/8) Cascade
  • Signal amplification
  • VEGFA-VEGFR2 Pathway
  • Toll Like Receptor TLR6:TLR2 Cascade
  • Activated TLR4 signalling
  • Activation of the AP-1 family of transcription factors
  • MyD88 cascade initiated on plasma membrane
  • MyD88:Mal cascade initiated on plasma membrane
  • TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
  • Innate Immune System
  • Signalling by NGF
  • MAP kinase activation in TLR cascade
  • NGF signalling via TRKA from the plasma membrane
  • MyD88-independent cascade
  • Mitochondrial biogenesis
  • Toll-Like Receptors Cascades
  • Toll Like Receptor 10 (TLR10) Cascade
  • DSCAM interactions
  • KSRP destabilizes mRNA
  • Oxidative Stress Induced Senescence
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • ERK/MAPK targets
  • MAPK targets/ Nuclear events mediated by MAP kinases
  • Nuclear Events (kinase and transcription factor activation)
  • Generic Transcription Pathway
  • Nuclear Receptor transcription pathway
  • 4-[5-[2-(1-Phenyl-Ethylamino)-Pyrimidin-4-Yl]-1-Methyl-4-(3-Trifluoromethylphenyl)-1h-Imidazol-2-Yl]-Piperidine
  • N-[(3z)-5-Tert-Butyl-2-Phenyl-1,2-Dihydro-3h-Pyrazol-3-Ylidene]-N\'-(4-Chlorophenyl)Urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • 1-(5-Tert-Butyl-2-P-Tolyl-2h-Pyrazol-3-Yl)-3-[4-(2-Morpholin-4-Yl-Ethoxy)-Naphthalen-1-Yl]-Urea
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • 5-(2,6-dichlorophenyl)-2-[(2,4-difluorophenyl)sulfanyl]-6H-pyrimido[1,6-b]pyridazin-6-one
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2\',6-dimethyl-4\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2\'-methyl-5\'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~\'-(cyclopropylmethyl)-6-methylbiphenyl-3,4\'-dicarboxamide
  • 3-{3-bromo-4-[(2,4-difluorobenzyl)oxy]-6-methyl-2-oxopyridin-1(2H)-yl}-N,4-dimethylbenzamide
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • 2-{4-[5-(4-chlorophenyl)-4-pyrimidin-4-yl-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxoethanol
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N\'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-FLUORO-N-1H-INDOL-5-YL-5-MORPHOLIN-4-YLBENZAMIDE
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[5-(4-FLUORO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-3H-IMIDAZOL-4-YL]-PYRIDINE
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
CSK and PTPN22 c-src tyrosine kinase protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
  • Costimulation by the CD28 family
  • GAB1 signalosome
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Signaling by EGFRvIII in Cancer
  • Platelet Aggregation (Plug Formation)
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by EGFR
  • TCR signaling
  • Signaling by EGFR in Cancer
  • PD-1 signaling
  • Platelet activation, signaling and aggregation
  • Phosphorylation of CD3 and TCR zeta chains
  • Adaptive Immune System
  • Staurosporine
CSNK2A1 and TCF7L2 casein kinase 2, alpha 1 polypeptide transcription factor 7-like 2 (T-cell specific, HMG-box)
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • (5-Oxo-5,6-Dihydro-Indolo[1,2-a]Quinazolin-7-Yl)-Acetic Acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • 3-METHYL-1,6,8-TRIHYDROXYANTHRAQUINONE
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N\'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
  • 5,6-dichloro-1-beta-D-ribofuranosyl-1H-benzimidazole
  • 1,2,5,8-tetrahydroxyanthracene-9,10-dione
  • Ellagic Acid
CSNK2A2 and TCF7L2 casein kinase 2, alpha prime polypeptide transcription factor 7-like 2 (T-cell specific, HMG-box)
  • Mitotic Prometaphase
  • Signal transduction by L1
  • Axon guidance
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • L1CAM interactions
  • Signaling by Wnt
  • Cell Cycle, Mitotic
  • M Phase
  • WNT mediated activation of DVL
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Signaling by WNT in cancer
  • Condensation of Prometaphase Chromosomes
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • S37 mutants of beta-catenin aren't phosphorylated
  • Peptide hormone metabolism
  • Degradation of beta-catenin by the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Incretin synthesis, secretion, and inactivation
  • truncations of AMER1 destabilize the destruction complex
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
CSTA and CTSH cystatin A (stefin A) cathepsin H
  • MHC class II antigen presentation
  • Adaptive Immune System
CSTB and CTSH cystatin B (stefin B) cathepsin H
  • MHC class II antigen presentation
  • Adaptive Immune System

Page 10 out of 155 pages